ERGO Projected Dividend Yield
Entia Biosciences Inc. ( OTCBB : ERGO )Entia Biosciences develops patented, pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2®. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease (CKD) and select neurodegenerative diseases. Co. also develops and markets health-related nutraceuticals and manufacture certain cosmeceuticals. ErgoD2 does not just apply in CKD, autism or Parkinson's, but also potentially in a number of auto-immune conditions in which iron is a factor, including diabetes, rheumatoid arthritis (joints), psoriasis (skin/nails), and alopecia (hair). 21 YEAR PERFORMANCE RESULTS |
ERGO Dividend History Detail ERGO Dividend News ERGO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |